Edwards Lifesciences

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell EW and other ETFs, options, and stocks.

About EW

Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care.

CEO

Bernard J. Zovighian

CEOBernard J. Zovighian

Employees

16,000

Employees16,000

Headquarters

Irvine, California

HeadquartersIrvine, California

Founded

1958

Founded1958

Employees

16,000

Employees16,000

EW Key Statistics

Market cap

48.63B

Market cap48.63B

Price-Earnings ratio

45.63

Price-Earnings ratio45.63

Dividend yield

—

Dividend yield—

Average volume

6.46M

Average volume6.46M

High today

$84.64

High today$84.64

Low today

$83.21

Low today$83.21

Open price

$83.68

Open price$83.68

Volume

337.32K

Volume337.32K

52 Week high

$87.89

52 Week high$87.89

52 Week low

$72.30

52 Week low$72.30

Stock Snapshot

As of today, Edwards Lifesciences(EW) shares are valued at $84.34. The company's market cap stands at 48.63B, with a P/E ratio of 45.63.

On 2026-05-04, Edwards Lifesciences(EW) stock traded between a low of $83.21 and a high of $84.64. Shares are currently priced at $84.34, which is +1.4% above the low and -0.3% below the high.

The Edwards Lifesciences(EW)'s current trading volume is 337.32K, compared to an average daily volume of 6.46M.

During the past year, Edwards Lifesciences(EW) stock moved between $72.30 at its lowest and $87.89 at its peak.

EW News

TipRanks 10h

Edwards Lifesciences Maintained at Buy as Strong Q1 Results and RESILIA Durability Data Support Elevated 2026 Outlook and Unchanged $97 Price Target

Josh Jennings, an analyst from TD Cowen, maintained the Buy rating on Edwards Lifesciences. The associated price target remains the same with $97.00. Unlock he...

TipRanks 21h

Edwards Lifesciences announces 10-year results from Commence aortic trial

Edwards Lifesciences (EW) announced 10-year results from the Commence aortic trial, reinforcing the long-term durability and sustained performance of its propri...

Simply Wall St 2d

Will Strong 10‑Year RESILIA Data and Higher 2026 Guidance Change Edwards Lifesciences' Narrative?

Edwards Lifesciences recently reported 10‑year results from its COMMENCE aortic trial, showing high freedom from valve deterioration and reoperation for patient...

Analyst ratings

76%

of 33 ratings

Buy

75.8%

Hold

24.2%

Sell

More EW News

Simply Wall St 4d

Reassessing Edwards Lifesciences Valuation As Investors Weigh Mixed Returns And Premium P/E

Advertisement Why Edwards Lifesciences (EW) is on investors’ radar today With no single headline event driving Edwards Lifesciences (EW) into focus, investors...

People also own

Based on the portfolios of people who own EW. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.